Using multiple AT products may be the best option for dry eye

Article

A study demonstrated the efficacies of three different artificial tears (AT) and that a combination of these may offer the best solution to corneal surface diseases affecting eye lubrication

A study featured in the European Journal of Ophthalmology has demonstrated the efficacies of three different artificial tears (AT) and that a combination of these may offer the best solution to corneal surface diseases affecting eye lubrication.

Dr Gil Calvão-Santos et al., Ophthalmology Department, Centro Hospitalar de Entre o Duoro e Vouga-Unidade de Santa Maria da Feira, Portugal, split 27 patients with dry eye symptoms into 4 groups. Group A was administered Tears Again, B was given Optive, C received Opticol and D was the control group.

Patients were observed on day 0, 7 and 30 after being administered the AT. Data analysis was conducted, as well as tear break-up time (TBUT), Schirmer tests and Ocular Surface Disease Index.

The findings demonstrated no significant differences between any of the groups. From day 0 to 30 the amount of eyes with abnormal TBUT was reduced. However, eyes presenting with an average TBUT increased in all groups and Schirmer value decreased in groups B, C and D, but increased in group A.

Tear film was recovered in all of the AT groups, but AT targeting just the internal and intermediate layer caused a small decline on lachrymal production. It was suggested that different types of AT should be used on different layers of the eye for the treatment of corneal surface diseases affecting eye lubrication.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.